The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

At the start of the month, the company spent $750 million to buy an early clinical-stage treatment that aims to treat a pair ...

Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Merck & Co Inc’s Profitability and Valuation Ratios Merck & Co Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 23.00% and a profit ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), ...